Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jan 16 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its recent approval from the USFDA. The company’s subsidiary, Zydus Pharmaceuticals (USA) Inc., received tentative approval to market Levomilnacipran Extended-Release Capsules. This medication is indicated for treating Major Depressive Disorder in adults and will be manufactured in Ahmedabad, India. The press release highlights the annual sales potential of the drug in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 16, 2023, titled "Zydus receives tentative approval from the USFDA forLevomilnacipran Extended-Release Capsules".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases